LifeSci Advisors Initiates Coverage of Cynapsus Therapeutics, Inc.
07 Fevereiro 2014 - 12:15PM
Marketwired
LifeSci Advisors Initiates Coverage of Cynapsus Therapeutics, Inc.
NEW YORK, NY--(Marketwired - Feb 7, 2014) - LifeSci Advisors,
LLC announcement for Cynapsus Therapeutics, Inc. (TSX-VENTURE: CTH)
(OTCQX: CYNAF)
- Sublingual Apomorphine Therapy Designed to Treat
Parkinson's Disease Freezing Episodes
- Following Positive Phase I Results, Cynapsus is Pursuing
505(b)(2) Approval for APL-130277
- Report Available for Download at
http://www.lifesciadvisors.com/clients/cynapsus/
LifeSci Advisors, LLC, a leading provider of investment research
and investor relations services in the life sciences sector, today
announced that it has initiated coverage of Cynapsus Therapeutics,
Inc. (TSX-VENTURE: CTH) (OTCQX: CYNAF), a company developing
APL-130277, a unique thin-film sublingual formulation of
apomorphine to treat freezing episodes in Parkinson's disease. The
sublingual strip is intended to replace a painful subcutaneous
injection that is currently the only available rescue therapy for
these episodes. The Company recently reported positive results from
a Phase I pharmacokinetic study. Pivotal efficacy studies in
apomorphine-naïve and apomorphine-experienced PD patients are
expected to begin in the fourth quarter of 2014, followed by a
safety study in 2015, leading to a potential regulatory filing in
early 2016.
"The sublingual strip that Cynapsus is developing has the
potential to substantially improve the treatment of 'off' episodes
for Parkinson's patients while also helping them avoid painful
injections," said Andrew I. McDonald, Ph.D., Founding Partner at
LifeSci Advisors. "Injection site reactions and the difficulty of
self-administration have hampered subcutaneous apomorphine, and
created an unmet medical need. The sublingual formulation has much
greater potential to penetrate the market."
On January 13 Cynapsus reported positive results from a Phase I,
CTH-103, comparing the pharmacokinetic profile of three doses of
sublingual apomorphine to subcutaneous injections. Results showed a
stronger safety profile for APL-130277 as compared to subcutaneous
injection, which should enable Cynapsus to pursue a differentiated
label from injectable apomorphine with possibly better safety
claims under 505(b)(2) regulatory approval.
In a 35 page Initiation Report by LifeSci Advisors, we explain
the potential advantages of Cynapsus' sublingual formulation of
apomorphine over the subcutaneous injection and other products in
development. The report explores the scientific basis for using
apomorphine to treat 'off' episodes in Parkinson's disease
patients. The addressable market is discussed, as well as the
potential for APL-130277 to increase the number of patients using
apomorphine to treat these episodes.
Dr. McDonald's full Initiation Report is available to download
at no cost at the LifeSci Advisors website,
www.lifesciadvisors.com. In addition to this Initiation
Report, LifeSci Advisors will also provide ongoing coverage and
event-based research updates on the Company as developments
occur.
The LifeSci Advisors research team is led by Dr. Andrew I.
McDonald, an industry veteran with more than 15 years of healthcare
industry experience. Prior to co-founding LSA, Dr. McDonald
was the Senior Biotechnology Analyst at Great Point Partners, a
leading health care investment firm with over $500 million under
management. Before Great Point, he was Co-Head of Healthcare
Research and Lead Biotechnology Analyst at ThinkEquity Partners, a
boutique investment banking firm focused on growth
companies. Dr. McDonald holds a Ph.D. in organic chemistry
from the University of California, Irvine, and, earlier in his
career, worked as a medicinal chemist at both Pfizer and
Cytokinetics.
About LifeSci
Advisors:
LifeSci Advisors (LSA) is a leading research firm and
communications consultancy dedicated to the life sciences industry.
The firm provides strategic counsel, customized marketing
communications, comprehensive research reports and investor
relations services to companies that specialize in the discovery,
development and commercialization of drugs, drug delivery systems,
medical devices and diagnostics. To learn more about LSA,
visit the company's website, www.lifesciadvisors.com.
Important
Disclosures:
The research report described in this press release is not
intended as an offering, recommendation, or a solicitation of an
offer to buy or sell securities. The securities discussed in
LSA research reports may be unsuitable for some investors depending
on their specific investment objectives, financial status, risk
profile, or particular needs. Investors should consider LSA reports
as only a single factor in making their investment decisions and
should not rely solely on these reports in evaluating whether or
not to buy or sell the securities of the subject
company. LifeSci Advisors has been compensated by the company
that is the subject of the report described and future research
reports, investor relations services, and general consulting
services. Please read each report's full disclosures and analyst
background on the LSA website, www.lifesciadvisors.com, before
investing. LifeSci Advisors is not a registered investment
adviser or broker-dealer.
Forward-looking
statements:
This press release contains forward-looking statements subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. These forward-looking
statements represent LSA's judgment as of the date of this release.
LifeSci Advisors disclaims, however, any intent or obligation to
update these forward-looking statements.
Media Contact: Michael Rice Phone: (646) 597-6979 Email:
mrice@lifesciadvisors.com Cynapsus Therapeutics Contact: Anthony
Giovinazzo President and CEO Phone: (416) 703-2449 x225 Email:
ajg@cynapsus.ca
Cotec (TSXV:CTH)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Cotec (TSXV:CTH)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
